CoChat
Sign Up
Cited by 253Acute Myeloid Leukemia ResearchHematological disorders and diagnosticsMultiple and Secondary Primary Cancers

Risks of myeloid malignancies in patients with autoimmune conditions

Open access
Anderson, L A, Pfeiffer, R M, Landgren, O, Gadalla, S, Berndt, S I, Engels, E A·2009·British Journal of Cancer
DOI 10.1038/sj.bjc.6604935PMC PMC2653768
Open this paper in CoChat — free accountOpen PDF

Abstract

Autoimmune conditions are associated with an elevated risk of lymphoproliferative malignancies, but few studies have investigated the risk of myeloid malignancies. From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13 486 myeloid malignancy patients (aged 67+ years) and 160 086 population-based controls were selected. Logistic regression models adjusted for gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for myeloid malignancies in relation to autoimmune conditions. Multiple comparisons were controlled for using the Bonferroni correction (P<0.0005). Autoimmune conditions, overall, were associated with an increased risk of acute myeloid leukaemia (AML) (OR 1.29) and myelodysplastic syndrome (MDS, OR 1.50). Specifically, AML was associated with rheumatoid arthritis (OR 1.28), systemic lupus erythematosus (OR 1.92), polymyalgia rheumatica (OR 1.73), autoimmune haemolytic anaemia (OR 3.74), systemic vasculitis (OR 6.23), ulcerative colitis (OR 1.72) and pernicious anaemia (OR 1.57). Myelodysplastic syndrome was associated with rheumatoid arthritis (OR1.52) and pernicious anaemia (OR 2.38). Overall, autoimmune conditions were not associated with chronic myeloid leukaemia (OR 1.09) or chronic myeloproliferative disorders (OR 1.15). Medications used to treat autoimmune conditions, shared genetic predisposition and/or direct infiltration of bone marrow by autoimmune conditions, could explain these excess risks of myeloid malignancies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604935

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The rarity of hematological malignancy among individuals with chronic inflammatory phenotypes, despite the relative increase in risk, is consistent with the self-limiting nature of chronic IL-1-induced expansion.

    “These data are consistent with the overall rarity of hematological malignancy among individuals with chronic inflammatory phenotypes, despite the relative increase in risk (Anderson et al., 2009; Gañán-Gómez et al., 2015).”

    From PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress (2021) · cites this paper as Anderson et al., 2009

    The Results (page unavailable) report increased relative risks of AML and MDS among people with autoimmune conditions. The paper does not establish that hematological malignancy remains rare in those individuals: its case-control analysis reports odds ratios, not their absolute risk. The claim about self-limiting IL-1-induced expansion is not in the cited sentence and is not attributed to this source. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. Alexson E, Brandt KD (1977) Acute leukemia after azathioprine treatment of connective tissue disease. Am J Med Sci 273: 335–340 266841
  2. Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA (2008) Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 17: 3069–3075 18957521 PMC2597453
  3. Anton E (2007) More on polymyalgia rheumatica (PMR) as a paraneoplastic rheumatic syndrome in the elderly (bicytopenia and PMR preceding acute myeloid leukemia). J Clin Rheumatol 13: 114 17414547
  4. Arbaje YM, Beltran G (1990) Chronic myelogenous leukemia complicated by autoimmune hemolytic anemia. Am J Med 88: 197–199 2301449
  5. Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A (2005a) Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54: 617–622 15831904 PMC1774486
  6. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L, Feltelius N (2005b) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64: 1414–1420 15843454 PMC1755232
  7. Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL (2001) Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 115: 320–322 11703328
  8. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854–862 11241255
  9. Dalamaga M, Petridou E, Cook FE, Trichopoulos D (2002) Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Causes Control 13: 603–608 12296507
  10. Demeter J, Messer G, Ramisch S, Mee JB, di Giovine FS, Schmid M, Herrmann F, Porzsolt F (1996) Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 2: 239–242 9384710
  11. Descatha A, Jenabian A, Conso F, Ameille J (2005) Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control 16: 939–953 16132803
  12. Deutsch M, Dourakis SP, Papanikolopoulos K, Belegrati M, Kalmantis T (2003) Autoimmune hemolytic anemia in a patient with acute myelocytic leukemia. Am J Hematol 74: 147 14508809
  13. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029–4038 18263783 PMC2288717
  14. Espinosa G, Font J, Munoz-Rodriguez FJ, Cervera R, Ingelmo M (2002) Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 21: 309–313 12189460
  15. Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C (2005) Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 113: 146–149 15802895
  16. Hemminki K, Li X, Sundquist J, Sundquist K (2008) Cancer risks in ulcerative colitis patients. Int J Cancer 123: 1417–1421 18561319
  17. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, Fraumeni JF (1993) Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 71: 745–750 8431855
  18. Kasim K, Levallois P, Abdous B, Auger P, Johnson KC (2005) Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control 16: 489–500 15986104
  19. Kwong YL, Au WY, Liang RH (1998) Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genet Cytogenet 104: 94–97 9666800
  20. Mok CC, Lau CS, Kumana CR (1996) Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient. Br J Rheumatol 35: 496–497 8646448
  21. Nisse C, Haguenoer JM, Grandbastien B, Preudhomme C, Fontaine B, Brillet JM, Lejeune R, Fenaux P (2001) Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol 112: 927–935 11298587
  22. Okamoto H, Teramura M, Kamatani N (2004) Myelodysplastic syndrome associated with low-dose methotrexate in rheumatoid arthritis. Ann Pharmacother 38: 172–173 14742816
  23. Pogoda JM, Katz J, McKean-Cowdin R, Nichols PW, Ross RK, Preston-Martin S (2005) Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Cancer 114: 634–638 15609330
  24. Preston-Martin S, Thomas DC, Yu MC, Henderson BE (1989) Diagnostic radiography as a risk factor for chronic myeloid and monocytic leukaemia (CML). Br J Cancer 59: 639–644 2713251 PMC2247133
  25. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M (2006) Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 42(17): 3028–3033 16945522
  26. Steurer M, Fritsche G, Tzankov A, Gotwald T, Sturm W, Konwalinka G, Gruber J (2004) Large-vessel arteritis and myelodysplastic syndrome: report of two cases. Eur J Haematol 73: 128–133 15245512
  27. Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85: 41–45 11437400 PMC2363903
  28. Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH (2005) Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 19: 1912–1918 16167059
  29. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG (2004) Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 34: 690–700 15473894
  30. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40: IV-3–IV-18 12187163
  31. Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2: 1088–1095 15625654
  32. Xu X, Talbott EO, Zborowski JV, Rager JR (2007) Cigarette smoking and the risk of adult leukemia: results from the Three Mile Island cohort study. Arch Environ Occup Health 62: 131–137 18400653
  33. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni Jr JF (1993) Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. Cancer Causes Control 4: 361–368 8347786
  34. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337–2344 16287762

Cited by

Sorted by citations

Authors
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A.
Affiliations
  • Queen's University Belfast (GB)
  • Division of Cancer Epidemiology and Genetics (US)
  • National Cancer Institute (US)
Corresponding author
Anderson, L A
ORCID
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2009-03
Volume
100
Issue
5
Pages
822-828
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
DOI
10.1038/sj.bjc.6604935
PMC
PMC2653768
OpenAlex
W2057266344
Cited by
253
References
0
Citations by year
2026: 7 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 15 · 2021: 26 · 2020: 16 · 2019: 18 · 2018: 21 · 2017: 16 · 2016: 18 · 2015: 16 · 2014: 21 · 2013: 15 · 2012: 12
FWCI
6.44
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health
  • Centers for Medicare and Medicaid Services
  • National Cancer Institute
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Emergency Medicine › Hematological disorders and diagnostics
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
myeloid neoplasms, autoimmune disease, acute myeloid leukemia, myelodysplastic syndrome, rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, autoimmune hemolytic anemia, systemic vasculitis, ulcerative colitis, pernicious anemia, chronic myeloid leukemia, myeloproliferative neoplasms, cancer risk, bone marrow involvement, immunosuppressants
MeSH terms
Aged, Aged, 80 and over, Autoimmune Diseases, Female, Humans, Male, Myelodysplastic Syndromes, Myeloproliferative Disorders, Risk Factors, Time Factors, Odds Ratio, Myelodysplastic-Myeloproliferative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review